Akero Therapeutics, Inc. (AKRO)


-0.91 (-1.85%)
Symbol AKRO
Price $48.34
Beta -0.909
Volume Avg. 0.78M
Market Cap 2.261B
Shares () -
52 Week Range 7.52-54.88
1y Target Est -
DCF Unlevered AKRO DCF ->
DCF Levered AKRO LDCF ->
ROE -60.13% Strong Sell
ROA -32.00% Strong Sell
Operating Margin -
Debt / Equity 10.45% Neutral
P/E -
P/B 5.44 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest AKRO news

Dr. Andrew Cheng
NASDAQ Global Select

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.